What’s in Store for Generics/Biosimilars?
By

The fortunes of the generics/biosimilars market will rest on one of the largest patent cliffs upcoming over the next five years. What do the numbers show, and what key trends are in the mix?

Ramping up the competition in generics/biosimilars market
A focus on healthcare cost containment from both payers and national governments bodes well for generics, but that sector continues to face competitive pressures. On a value basis, the global generics market in 2021 was $305 billion, according to IQVIA estimates, up from a 2016 level of $265 billion. The developed markets of the US, Japan, the EU 4 (France, Germany, Italy, and Spain), and the UK, accounted for a combined 46% of the $305-billion global generics market in 2021.

The generics sector, always highly cost competitive, continues to see pricing pressures, particularly in the US. Indian manufacturers have gained significant share of the US market since 2016, driven by a lower cost base that has allowed for aggressive price discounting. Prices have declined by more than 30% since 2016.

Despite these pressures, the near-term fortunes of the generics and biosimilars sector will largely rest on one of the largest patent cliffs upcoming over the next five years (2022–2026) with a cumulative brand loss by innovators of $188 billion in developed markets (see Figure 1). The resulting revenue opportunities for the generics and biosimilar sectors are significant: $17 billion for generics and $39 billion for biosimilars for the period 2022–2026, according to IQVIA estimates.

US market generics/biosimilars market
Most of the impact from loss of exclusivity of protected brands in 2021 in the US market was from biosimilars introduced in the prior three years, including three molecules in the oncology market—bevacizumab, rituximab, and trastuzumab, according to a new report by the IQVIA Institute for Human Data Science, The Use of Medicines in the U.S. 2022: Usage and Spending Trends and Outlook to 2026. Biologic brand losses were $10 billion in both 2020 and 2021, an increase from the $5 billion in 2019 and totaling $31 billion in the past five years (2017–2021) (see Figure 2). In the same five-year period, small-molecule brand losses were $62 billion, down from $84 billion in the prior five-year period (2016–2020).

Recent Feature Articles

Manufacturing and Supply: The Impact Factors for 2023
By

By
What are key issues impacting bio/pharma manufacturing and supply in 2023? DCAT Value Chain Insights takes an inside look at what is on the industry’s radar.

Global Spending & Demand for Medicines: Up or Down?
By

By
Global demand & spending for medicines will increase to $1.9 trillion by 2027. COVID-19 vaccines will continue to be a growth driver, but what else is in play?

The Year Ahead: What’s on the Minds of CEOs?
By

By
Economic uncertainty, supply chain, talent management, and risk mitigation were key issues cited by CEOs in PwC’s Global CEO survey, released at the World Economic Forum in Davos, Switzerland. What are key takeaways from a study of 4,400 CEOs?

Big Pharma’s Growth Initiatives in 2023: Part 2
By

By
More coverage of the J.P. Morgan Annual Healthcare Conference in San Francisco earlier this month, where bio/pharma industry executives highlighted their companies’ strategies and key growth initiatives. What are more highlights?